title: Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.
abstract: OBJECTIVE
  Prostate cancer in men age 50 years or younger traditionally has accounted for approximately 1% of those diagnosed with prostate cancer. Prior studies of prostate cancer in men of this age led many clinicians to believe that they have a less favorable outcome than older men. Most of these studies were conducted before the advent of prostate specific antigen (PSA) screening programs. We evaluated a surgically treated cohort of men age 50 years or younger to determine whether disease recurred more frequently among them than in those 51 to 69 years old in the PSA era.
  
  
  METHODS
  We reviewed the medical records of 477 men who underwent radical prostatectomy between 1988 and 1997. Age, ethnicity, preoperative PSA, clinical and pathological stage, margin and seminal vesicle involvement, and recurrence were compared between 79 men age 50 years or younger (study group) and 398, 51 to 69 years old (comparison group). Disease-free survival rates were compared using Kaplan-Meier and Cox regression techniques.
  
  
  RESULTS
  There were 6 (7.6%) recurrences in the study group (79) and 107 (26.9%) in the comparison group (398). The disease-free survival curves were significantly different (log-rank p = 0.010). Age remained a significant prognostic factor (Wald p = 0.033) in multivariate Cox regression analyses that controlled for race, clinical and pathological stage, and pretreatment PSA. Similar results were found when the comparison group was limited to 116 patients 51 to 59 years old (log-rank p = 0.034, Wald p = 0.069).
  
  
  CONCLUSIONS
  These data suggest that patients in the PSA era who underwent radical prostatectomy and were age 50 years or younger have a more favorable disease-free outcome compared to older men.
authors.affiliation: Department of Surgery, Urology Service, Walter Reed Army Medical Center, Washington, DC, USA.
authors.forename: C V
authors.initials: CV
authors.lastname: Smith
authors.forename: J J
authors.initials: JJ
authors.lastname: Bauer
authors.forename: R R
authors.initials: RR
authors.lastname: Connelly
authors.forename: T
authors.initials: T
authors.lastname: Seay
authors.forename: C
authors.initials: C
authors.lastname: Kane
authors.forename: J
authors.initials: J
authors.lastname: Foley
authors.forename: J B
authors.initials: JB
authors.lastname: Thrasher
authors.forename: L
authors.initials: L
authors.lastname: Kusuda
authors.forename: J W
authors.initials: JW
authors.lastname: Moul
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D000367:Age Factors; D000368:Aged; D016208:Databases, Factual; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000032:analysis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D012189:Retrospective Studies
chemical_list: D017430:Prostate-Specific Antigen